Trial Profile
A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary)
- Indications Generalised seizures; Pain; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors UCB Biopharma
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 24 Mar 2017 New trial record